Search clinical trials for: AP09004

Total 7 results

Allergan
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

Completed

Phase 3 Study of MAP0004 in Adult Migraineurs (FREEDOM301)

Migraine Disorders

United States
Intec Pharma Ltd.

Completed

An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's Disease

Parkinson's Disease

Israel
Luye Pharma Group Ltd.
Shan Dong Boan Biotechnology Co., Ltd(Co-sponsor)

Not yet recruiting

A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD）

Age Related Macular Degeneration
Allergan
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

Completed

Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers

Healthy Subjects

United Kingdom
Allergan
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

Completed

QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo

Healthy

United States
Allergan
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

Completed

Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure

Healthy

United States
Allergan
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

Completed

Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole

Healthy

United Kingdom

3

Subscribe